Loading…
← CockpitCompetitor Analysis › PHAT Phathom Pharmaceuticals, Inc.Open in the cockpit ↗

Phathom Pharmaceuticals, Inc.PHATCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major
Momentum laggard 8
Mkt cap
$431M
US dollars, full cap
Free float
63%
of shares outstanding
$/day
$11.3M
20-day average traded
Fwd P/E
39.5×
forward earnings
ROIC−WACC
-93.3 pp
WACC 6.9%
Hurdle
n/a
no reverse DCF
Next earnings
104 days
2 Mar 2027
Close · USD$5.30
1D-3.6%
1W-15.6%
1M-27.5%
3M-38.4%
6M-55.4%
YTD-68.0%
1Y-63.2%
ATR %9.9%
Beta0.96
52w lowhigh71.0% off high

What Phathom Pharmaceuticals does

Employees: 371

Phathom Pharmaceuticals at a glance

Size Phathom Pharmaceuticals (PHAT) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $431M, the 2786th largest of 3,085 United States companies the cockpit tracks. Shares closed at $5.30 on 18 Nov 2026.

Performance Over six months the shares fell 55.4%, against -23.1% for the median peer and -2.2% for the United States market (cap-weighted) — lowest of 21 in its peer set.

Growth Revenue grew 86.8% over the last twelve months (peer median +4.9%); the operating margin is -9.3% (peer median 4.0%).

Valuation It trades at 39.5× forward earnings against a peer median of 12.2× (most expensive of 7).

Capital Return on invested capital runs 93.3 points below its cost of capital (6.9% WACC).

Short interest Short interest is 11.3% of the free float (30 Oct 2026).

Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).

Relative performance

40608010021 May 202621 Aug 202618 Nov 2026Peer median 78PHAT 46
Six months, rebased to 100: Phathom Pharmaceuticals against the median of its 20 peers (local-currency closes).

Phathom Pharmaceuticals financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$275M$175M$55.3M$682,000$0
Revenue growth—+217%+8,001%——
Gross profit$222M$153M$47.3M-$60,000-$620,000
EBITDA-$25.0M-$159M-$277M-$167M-$172M
Net income-$83.0M-$221M-$334M-$202M-$198M
Free cash flow-$21.0M-$167M-$267M-$139M-$148M
Capital expenditure$302,000$229,000$135,000$1.63M$1.04M
Total debt$555M$589M$555M$446M$214M

Quarterly statements and history in the cockpit →

Phathom Pharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%-20%-10%002923688117605077688136600613ZOTAOVID0005180007880029000484104114601089001060TVGN002462603139RPGLIFE002728603811PHAT6-month return →1-month return →
Up and to the right = strong over both horizons. Phathom Pharmaceuticals is the large dot.

Fundamentals: revenue growth against valuation

0%+25%+50%+75%10×20×30×40×688117605077688136601089001060002728PHATRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Phathom Pharmaceuticals is the large dot.

Phathom Pharmaceuticals competitors and peer comparison

How Phathom Pharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Phathom Pharmaceuticals against its 20 peers (data as of 18 Nov 2026)
MeasurePHATPeer medianRank in peer set
1-month return-27.5%-11.5%2nd lowest of 21
6-month return-55.4%-23.1%lowest of 21
Distance from 52-week high-71.0%-44.7%3rd lowest of 21
Revenue growth (TTM)+86.8%+4.9%highest of 20
Operating margin-9.3%4.0%8th lowest of 20
Forward P/E39.5×12.2×most expensive of 7
ROIC minus cost of capital-93.3 pp-2.5 pplowest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Phathom Pharmaceuticals PHATUnited States$431M-55%+87%-9%39.5×n/an/a
Zhuhai Rundu Pharmaceutical 002923.SZChina$430M-30%+14%5%n/a1.4%-1.3%
Cheng Du Sheng Nuo Biotec 688117.SSChina$433M-48%+51%27%12.5×-0.2%+14.5%
Zhejiang Huakang Pharmaceutical 605077.SSChina$433M-47%+35%4%10.3×n/an/a
Kexing Biopharm 688136.SSChina$433M-42%-14%-12%23.1×n/an/a
Shanghai Shenqi Pharmaceutical Investment Management 600613.SSChina$427M+4%-4%3%n/a10.6%+1.4%
Zota Health Care ZOTA.NSIndia$427M+9%+69%-16%n/an/an/a
Ovid Therapeutics OVIDUnited States$427M-5%-78%-4,700%n/an/an/a
Jiangsu Sihuan Bioengineering 000518.SZChina$437M-8%-17%-28%n/an/an/a
PKU Healthcare 000788.SZChina$437M-12%-49%5%n/a-5.6%-5.6%
Harbin Medisan Pharmaceutical 002900.SZChina$437M-16%-5%-29%n/an/an/a
Hyundai Bioscience 048410.KSSouth Korea$424M-50%+78%-580%n/an/an/a
Synmosa Biopharma 4114.TWOTaiwan$423M-1%+21%10%n/a5.4%+15.3%
Beijing Foyou Pharma 601089.SSChina$423M-27%+5%10%11.8×n/an/a
JW Pharmaceutical 001060.KSSouth Korea$423M-26%+9%13%6.3×-15.4%+7.2%
Tevogen TVGNUnited States$422M-38%n/an/an/an/an/a
Cachet Pharmaceutical 002462.SZChina$441M-25%-14%0%n/a-9.9%-3.4%
Shaanxi Kanghui Pharmaceutical Co 603139.SSChina$421M-31%+1%-39%n/an/an/a
RPG Life Sciences RPGLIFE.NSIndia$443M+10%+15%17%n/an/an/a
Teyi Pharmaceutical 002728.SZChina$419M-12%-7%7%28.0×24.4%+8.0%
Zhejiang Chengyi Pharmaceutical 603811.SSChina$445M-21%+5%19%n/a1.3%+1.3%

Questions

Which companies are Phathom Pharmaceuticals's closest peers?
The cockpit's peer set: Zhuhai Rundu Pharmaceutical (002923.SZ), Cheng Du Sheng Nuo Biotec (688117.SS), Zhejiang Huakang Pharmaceutical (605077.SS), Kexing Biopharm (688136.SS), Shanghai Shenqi Pharmaceutical Investment Management (600613.SS), Zota Health Care (ZOTA.NS), Ovid Therapeutics (OVID), Jiangsu Sihuan Bioengineering (000518.SZ).
Is Phathom Pharmaceuticals expensive compared with its peers?
On forward p/e it trades at 39.5× against a peer median of 12.2×, most expensive of 7 in its peer set.
How has Phathom Pharmaceuticals stock performed?
Over six months to 18 Nov 2026 the shares returned -55.4% against -23.1% for the median peer; over one year -63.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.